Table 11

Significance of transcription factors in LUAD
Stage/DNA methylated genes identified as TFs Significance
Common across Stages (Table2)
FOXG1 Cell adhesion, Growth and invasion of lung cancer [68] and is prognostic marker in bladder cancer [69]
HAND2 Identified in early stage in squamous cell carcinoma but not in adenocarcinoma [70]
HOXB4 Overexpression identified in ovarian cancer though HOX genes are reported in lung cancer [71]
PHOX2A Abnormal methylation in NSCLC [72]
Unique TFs in Stage I (total 6)
HLA-G Potential biomarker in lung cancer [73]
BCL11B A new therapeutic for T-cell malignancies but direct correlation with lung cancer not available [74,75]
UTF1 Not yet correlated in lung cancer but a prognostic in cervical cancer [76]
Unique TFs in Stage II (total 6)
EMX2 Is associated with WNT signaling pathway and its down-regulation is associated with methylation of promoter region in lung cancer suggesting it as novel suppressor gene for human lung cancer [77]
NKX6-2 Identified as methylated in lung cancer [40] and identified as target in Pancreatic cancer [78]
OLIG2 Identified in lung cancer but not study as target [79]
ZNF577 Identified as methylated in various cancers like breast and oropharyngeal squamous cell carcinoma, very recently in lung cancer [80]. Not much is reported with respect to its prognostic value.
Unique TFs in Stage III (total 13)
EPO Is the key regulator in the production of RBC, methylation of the promoter section of EPO is identified in many cancers including lung, breast liver etc. [81] though its prognostic value efficiency is not reported.
GERM1 Hypermethylation of GREM1 is identified for prognostic significance in renal cell carcinoma [82], so far not in lung cancer.
IRX1 Methylation is identified in lung cancer [83] but needs to be studied for prognostic markers.

Pradhan et al.

Pradhan et al. BMC Systems Biology 2013 7:141   doi:10.1186/1752-0509-7-141

Open Data